In the ever-evolving landscape of biomedical research, the comprehensive mapping of proteins and their modifications across diverse human body fluids stands as a critical frontier. Proteins, indispensable to cellular function and signaling, are extensively modified by glycans—complex sugar chains that intricately influence protein behavior through a process termed glycosylation. This molecular decoration modulates protein activity, stability, and localization, and alterations in glycosylation patterns have been implicated as early indicators of pathological conditions such as cancer, autoimmune diseases, and metabolic disorders. Despite the recognized importance, the scientific community has lacked a systematic, standardized resource encompassing both proteomic and glycoproteomic profiles across a spectrum of clinically relevant body fluids. Addressing this significant gap, a research group led by Dr. Yong Zhang at West China Hospital, Sichuan University, has pioneered the GlycoHBF dataset—a groundbreaking mass spectrometry-based glycoproteomics atlas derived from 15 distinct human body fluid types.
This ambitious project undertook the collection and exhaustive analysis of body fluids ranging from the commonly studied plasma, urine, and cerebrospinal fluid to less frequently explored specimens such as tears, sweat, bile, and synovial fluid obtained from joints. Crucially, the team established a strictly standardized methodological workflow ensuring uniform sample collection, processing, and analytical rigor. Employing state-of-the-art liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS), they executed dual-layer profiling capturing both the protein constituents and intact N-glycopeptides. This uniformity in protocol circumvented the confounding effects of methodological variability that have plagued earlier studies, facilitating direct comparisons across samples and enhancing data reproducibility.
Their proteomic surveys illuminated the extensive diversity and specificity of protein compositions across different fluids. While a subset of proteins was ubiquitously expressed in multiple fluids, each fluid bore a distinct molecular fingerprint, reflective of its physiological and anatomical origins. Even more striking was the differential glycosylation landscape; modifications exhibited pronounced fluid-specific patterns that not only underscored the biochemical uniqueness of each body fluid but also suggested a nuanced layer of regulation and local microenvironment influence. These distinctive glycosylation signatures imply potential avenues for achieving highly sensitive and specific biomarkers unattainable by protein abundance alone.
The GlycoHBF study leveraged cutting-edge analytical strategies to surmount challenges inherent in glycoproteomics. By integrating Data-Independent Acquisition (DIA) mass spectrometry for protein quantification with an innovative fusion of Electron-Transfer/Higher-Energy Collision Dissociation (EThcD) and stepped collision energy Higher-energy Collisional Dissociation (sceHCD) fragmentation techniques for glycopeptide characterization, the researchers attained unprecedented depth and precision. This dual-fragmentation approach facilitates robust identification and site-specific annotation of intact N-glycopeptides—a pivotal advancement given the structural complexity and heterogeneity of glycan modifications.
Through this comprehensive and rigorous approach, the dataset revealed previously underappreciated biological intricacies governing protein glycosylation dynamics in human biofluids. Subtle variations in glycan structures were discernible across fluids, reflecting the distinct biosynthetic machineries and enzymatic environments operating in different tissue microenvironments. Such insights illuminate the multifaceted role of glycosylation not only as a modulator of protein function but as a finely tuned molecular code orchestrating intercellular communication, immune recognition, and disease manifestation.
Researchers and clinicians stand to benefit immensely from the GlycoHBF resource, which is publicly accessible via the iProX database (accession PXD068799). This open-access repository sets a new benchmark for transparency and reproducibility, enabling the broader scientific community to harness these data for biomarker discovery, therapeutic target validation, and the elucidation of disease mechanisms. By providing a comprehensive baseline of healthy body fluid molecular profiles, GlycoHBF equips researchers to distinguish between physiological variation and pathological perturbations with greater fidelity.
A key implication of this work lies in advancing the field of liquid biopsy—minimally invasive diagnostic approaches that rely on detecting biochemical signatures in body fluids. Given the distinct molecular landscapes delineated for fluids such as cerebrospinal fluid (relevant for neurological diseases), pleural fluid (for pulmonary conditions), urine (renal pathologies), and synovial fluid (joint disorders), GlycoHBF paves the way for tailored biomarker panels with heightened diagnostic and prognostic accuracy. Standardized protocols outlined in this study provide a translational roadmap for clinical researchers aiming to integrate glycoproteomic assays into routine diagnostics.
The rigor and innovation of this study also highlight the critical importance of integrating glycosylation profiling alongside traditional proteomics. While protein expression changes are informative, the glycan moieties confer additional complexity and specificity, reflecting cellular states and environmental cues not captured by proteomic data alone. Recognizing glycosylation as a dynamic and context-dependent modification underscores the potential for novel biomarkers capable of early detection and precise disease stratification.
Furthermore, this research contributes methodological advancements with wider applicability. The integration of dual fragmentation MS techniques sets a new standard for glycoproteomic analyses, facilitating comprehensive site-specific glycan characterization that can be applied to various biological specimens and disease models. Such technology empowers future studies to delve deeper into the functional implications of glycosylation alterations and their interplay with disease pathways.
In synthesizing extensive protein and glycan data across multiple human biofluids, the GlycoHBF consortium has effectively constructed a molecular atlas that transcends traditional single-fluid studies. This holistic perspective fosters a systems biology understanding of human physiology and pathology, potentially guiding therapeutic interventions that target aberrant glycosylation processes. By illuminating the molecular heterogeneity within and across body fluids, this research lays foundational knowledge critical for precision medicine’s evolution.
Collectively, these findings underscore a paradigm shift towards multi-omic, high-resolution profiling of human biofluids. The GlycoHBF dataset is a vital resource ushering in a new era wherein protein and glycan modifications are interrogated in concert, unlocking deeper insights into human health and disease. The dataset’s availability and methodological transparency amplify its impact, promising to accelerate discoveries that transform diagnostics, prognostics, and therapeutic development in diverse medical disciplines.
Subject of Research: Human tissue samples
Article Title: GlycoHBF: Mass spectrometry-based glycoproteomics data from 15 types of human body fluids
Web References:
https://doi.org/10.1016/j.glycos.2026.100034
iProX Database (PXD068799)
Image Credits: Yong Zhang
Keywords
Glycosylation, Glycoproteomics, Mass Spectrometry, Liquid Biopsy, Human Body Fluids, Protein Profiling, N-Glycopeptides, DIA-MS, EThcD-sceHCD, Biomarkers, Precision Medicine, Proteomics
Tags: body fluid proteomicscerebrospinal fluid glycoproteomicsclinical glycoproteome resourceGlycoHBF atlasglycoproteins in tears and sweatglycosylation in disease biomarkershuman glycoproteome mappingmass spectrometry glycoproteomicsplasma glycoprotein analysisprotein glycosylation profilesstandardized glycoproteomics workflowsynovial fluid protein profiling
